LIGAND PHARMACEUTICALS INC (LGND): Regulation FD Disclosure
LIGAND PHARMACEUTICALS INC (LGND) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million JUPITER, Fla., September 24, 2026 – Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it has entered into a f
How this was made
The 30-second read
Why it matters
The agreement provides up to $41 million for royalty rights and $6 million in Series C equity, potentially expanding Ligand's royalty portfolio and cash flow.
Market read
New financing adds to Ligand's revenue pipeline and may influence its stock price.
What to watch
Future royalty rates depend on funding amount; downside risk if AvenCell's programs stall.
Background
Ligand Pharmaceuticals, a royalty aggregator, announced a new financing partnership with clinical‑stage cell‑therapy company AvenCell Therapeutics.
Ticker impact
Ligand Pharmaceuticals disclosed a financing agreement to invest up to $47 million in AvenCell Therapeutics, receiving royalty rights on future sales.
Potential modest upside as investors price in new royalty upside and cash deployment.
Financing deals of this size are material for Ligand's revenue base and are disclosed for the first time, providing fresh information for valuation.
Market effects
Highlights continued investor interest in royalty‑based biotech financing models.
US biotech financing activity may see slight uplift.
Limited to biotech/royalty sector.
Counterpoint
The deal may dilute Ligand's balance sheet if milestones are not met, limiting upside.
Key entities
- companyLigand Pharmaceuticals
US‑listed royalty aggregator (NASDAQ: LGND).
- companyAvenCell Therapeutics
Clinical‑stage cell‑therapy developer (private).
